Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIIb, Open-label, Hybrid Type III Trial Evaluating Implementation Strategies for Long-acting Cabotegravir Plus Long-acting Rilpivirine Every Two Months in HIV-1 Infected, Virologically Suppressed Adults in Select European Healthcare Settings

Next Previous
X
Search
Trial Profile

A Phase IIIb, Open-label, Hybrid Type III Trial Evaluating Implementation Strategies for Long-acting Cabotegravir Plus Long-acting Rilpivirine Every Two Months in HIV-1 Infected, Virologically Suppressed Adults in Select European Healthcare Settings

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Cabotegravir+rilpivirine (Primary) ; Cabotegravir+rilpivirine (Primary) ; Rilpivirine (Primary) ; Rilpivirine (Primary)
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms CARISEL
  • Sponsors ViiV Healthcare

    • Most Recent Events

    • 18 Oct 2023 According to a ViiV Healthcare media release, data from this study will be presented at the 19th Annual European AIDS Conference (EACS 2023)
    • 24 Apr 2023 Status changed from active, no longer recruiting to completed.
    • 10 Apr 2023 This trial has been completed in Germany (End Date: 13 Mar 2023), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top